New SullivanCotter data show physician compensation continuing to rise faster than productivity across major US specialty groups. Median total cash compensation increased across all major specialty categories, with adult medical specialties recording a 7.2% year-on-year increase while productivity growth remained comparatively modest. The findings highlight ongoing pressure on healthcare organisations as physician labour costs rise faster than output, with particularly strong compensation growth also reported in specialties including anesthesiology and radiology. Field Content Alert Type Compensation Organisation SullivanCotter Report 2026 Physician Compensation and Productivity Survey Geography United States Metric Median total cash compensation Overall Trend Physician compensation growth continued to outpace productivity growth across major specialty groups Adult Medical Specialties Median total cash compensation increased 7.2% year-on-year Highlighted Specialties Anesthesiology; radiology What Happened SullivanCotter reported continued physician compensation growth across all major specialty groups while corresponding productivity increases remained smaller. Why It Matters Compensation rising faster than productivity increases financial pressure on hospitals and medical groups and may affect recruitment strategy, service-line economics and physician workforce planning. Supporting Context Healthcare organisations continue to compete for physicians amid workforce shortages, increasing demand and specialty-specific recruiting pressure. Potential Impact Persistent divergence between pay and productivity could increase operating costs and force employers to reconsider compensation models, staffing structures and service delivery. Key Takeaway US physician pay continues to rise faster than productivity, with adult medical specialties showing particularly strong year-on-year compensation growth. What to Watch Whether compensation growth moderates, how productivity trends respond and which specialties experience the greatest future recruitment pressure. Primary Source SullivanCotter Relevant Date 17 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved Fayuvi as the first gene therapy for children with Sanfilippo syndrome type A, introducing the first treatment designed to address the underlying cause of the rare neurodegenerative disorder. Fayuvi, or rebisufligene etisparvovec-hopf, is approved for paediatric patients with mucopolysaccharidosis type IIIA and delivers a functional copy of the SGSH gene to support production of the deficient enzyme. The approval marks a major milestone for families affected by Sanfilippo syndrome type A, a progressive inherited condition that previously had no approved disease-modifying treatment. Field Content Alert Type Approval Drug Name Rebisufligene etisparvovec-hopf Brand Name Fayuvi Company Ultragenyx Pharmaceutical Regulatory Authority U.S. Food and Drug Administration Approval Type Gene therapy approval Indication Paediatric patients with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome type A Therapy Area(s) Rare disease; neurology; genetic disease Technology or Modality AAV-based gene therapy Target SGSH gene / heparan N-sulfatase deficiency Geography United States What Happened The FDA approved Fayuvi as the first gene therapy and first approved treatment for paediatric patients with Sanfilippo syndrome type A. Why It Matters The approval introduces the first disease-modifying option for a progressive neurodegenerative disorder that previously had no approved treatment targeting the underlying genetic cause. Supporting Context Sanfilippo syndrome type A is caused by pathogenic variants in the SGSH gene, resulting in deficiency of the heparan N-sulfatase enzyme and progressive accumulation of heparan sulfate. Key Takeaway Fayuvi becomes the first approved therapy for Sanfilippo syndrome type A and a major new milestone in paediatric gene therapy. What to Watch Commercial rollout, treatment-centre readiness, long-term follow-up and real-world evidence on neurological and developmental outcomes. Primary Source U.S. Food and Drug Administration Relevant Date 17 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has expanded the approved use of Kerendia to adults with chronic kidney disease associated with type 1 diabetes, introducing a new treatment option for this high-risk population. Kerendia, or finerenone, is a non-steroidal mineralocorticoid receptor antagonist already used in chronic kidney disease associated with type 2 diabetes and can now also be prescribed for eligible adults with type 1 diabetes. The expanded indication addresses an area with limited therapeutic innovation and gives clinicians another option for reducing kidney and cardiovascular risks associated with diabetic kidney disease. Field Content Alert Type Approval Drug Name Finerenone Brand Name Kerendia Company Bayer Regulatory Authority U.S. Food and Drug Administration Approval Type Indication expansion Indication Chronic kidney disease associated with type 1 diabetes in adults Therapy Area(s) Nephrology; diabetes; cardiometabolic disease Technology or Modality Non-steroidal mineralocorticoid receptor antagonist Geography United States What Happened The FDA approved Kerendia for adults with chronic kidney disease associated with type 1 diabetes. Why It Matters The approval creates a new treatment option for a population with substantial kidney and cardiovascular risk and historically limited disease-specific pharmacological choices. Supporting Context Finerenone is already approved for chronic kidney disease associated with type 2 diabetes and acts by selectively blocking mineralocorticoid receptor overactivation. Key Takeaway Kerendia's FDA label now includes adults with chronic kidney disease associated with type 1 diabetes. What to Watch Clinical adoption, incorporation into kidney-disease treatment pathways and real-world outcomes in people with type 1 diabetes. Primary Source Bayer Relevant Date 17 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Roche and Dualitas Therapeutics have entered a large-scale bispecific antibody discovery collaboration potentially worth more than $1 billion across immunology and inflammation programmes. Roche will pay Dualitas $36.5 million upfront to screen more than 300,000 bispecific antibody combinations using Dualitas' discovery platform against selected therapeutic targets. The collaboration combines Roche's development capabilities with high-throughput bispecific screening and gives Dualitas potential milestone and commercial payments exceeding $1 billion. Field Content Alert Type Deal Companies Roche; Dualitas Therapeutics Deal Type Discovery and licensing collaboration Asset or Company Bispecific antibody discovery platform Therapy Area(s) Immunology; inflammation Technology or Modality Bispecific antibodies; high-throughput antibody screening Deal Value US$36.5 million upfront with total potential economics exceeding US$1 billion Screening Scale More than 300,000 bispecific combinations Geography Global What Happened Roche entered a discovery collaboration with Dualitas to identify bispecific antibody candidates for selected immunology and inflammation targets. Why It Matters The agreement applies high-throughput screening to a very large bispecific design space, potentially accelerating identification of differentiated therapeutic combinations. Supporting Context Dualitas' platform is designed to generate and screen large libraries of bispecific antibodies to identify combinations with desirable biological activity and drug properties. Strategic Rationale Roche gains access to a scalable bispecific discovery engine while Dualitas receives upfront funding and substantial milestone-based economics. Potential Impact Successful programmes could generate new biologic therapies for inflammatory and immune-mediated diseases. Key Takeaway Roche is paying US$36.5 million upfront in a bispecific discovery collaboration with Dualitas carrying more than US$1 billion in potential total value. What to Watch Selection of development candidates, advancement into preclinical studies and disclosure of specific disease targets. Primary Source Fierce Biotech Relevant Date 17 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Medovate and JEB Technologies are combining into a single medical-device company under the Medovate name, integrating product development, manufacturing, regulatory and commercial capabilities. The combined organisation will bring together Medovate's international commercial platform and medical-device portfolio with JEB Technologies' engineering and manufacturing capabilities. The consolidation is intended to create a vertically integrated medtech business able to take devices from concept through regulatory approval, manufacturing and global commercialisation. Field Content Alert Type Deal Companies Medovate; JEB Technologies Deal Type Corporate combination / merger Asset or Company Combined business operating under the Medovate name Sector Medical devices; medtech Technology or Modality Medical-device development and manufacturing Deal Value Financial terms were not disclosed Geography United Kingdom; international What Happened Medovate and JEB Technologies agreed to combine into one medical-device company operating under the Medovate brand. Why It Matters The transaction creates a more integrated medtech organisation spanning design, engineering, manufacturing, regulatory approval and international commercialisation. Supporting Context Medovate specialises in developing and commercialising clinician-led medical technologies, while JEB Technologies provides product-development and manufacturing capabilities. Strategic Rationale Combining the businesses creates an end-to-end platform capable of supporting medical devices from initial concept through commercial-scale production and market launch. Potential Impact The integrated model could shorten development timelines and give external innovators a single partner for design, regulatory, manufacturing and commercialisation services. Key Takeaway Medovate and JEB Technologies are consolidating into one vertically integrated medical-device company. What to Watch Formal launch of the combined company on 21 September and subsequent portfolio, customer and international expansion plans. Primary Source Medovate / JEB Technologies Relevant Date 16 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Henlius has received approval in Pakistan for HANDAYUAN, its adalimumab biosimilar, marking the product's first regulatory approval outside China. The biosimilar, marketed locally as Adaliget, has been approved by Pakistan's Drug Regulatory Authority across the indications authorised for the reference adalimumab product in the country. The approval advances Henlius' international biosimilar strategy and expands access to an established TNF inhibitor used across multiple inflammatory and autoimmune diseases. Field Content Alert Type Approval Drug Name Adalimumab biosimilar Brand Name HANDAYUAN / Adaliget Company Henlius Regulatory Authority Drug Regulatory Authority of Pakistan Approval Type Marketing approval Reference Product Adalimumab reference biologic Indication All indications of the reference adalimumab product approved in Pakistan Therapy Area(s) Immunology; inflammatory disease; autoimmune disease Technology or Modality Biosimilar monoclonal antibody; TNF inhibitor Geography Pakistan What Happened Pakistan's Drug Regulatory Authority approved Henlius' adalimumab biosimilar HANDAYUAN, marketed locally as Adaliget. Why It Matters The decision is HANDAYUAN's first approval outside China and expands Henlius' international commercial footprint in biosimilars. Supporting Context Adalimumab is a TNF-targeting monoclonal antibody used across a wide range of inflammatory and autoimmune diseases. Key Takeaway Henlius has secured the first overseas approval for HANDAYUAN with regulatory clearance in Pakistan. What to Watch Commercial launch in Pakistan and additional international regulatory filings and approvals for HANDAYUAN. Primary Source Henlius Relevant Date 16 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Zealand Pharma has licensed its GLP-1/gastrin dual-agonist peptide platform to Elvinix for development as a potentially regenerative treatment for type 1 diabetes. Elvinix receives rights to Zealand's preclinical peptide platform and associated data package, which is intended to stimulate pancreatic beta-cell regeneration while supporting metabolic control. The deal transfers a non-core early-stage programme to a dedicated development company while preserving the potential for a disease-modifying approach to type 1 diabetes. Field Content Alert Type Deal Companies Zealand Pharma; Elvinix Deal Type Exclusive licensing agreement Asset or Company GLP-1/gastrin dual-agonist peptide platform Therapy Area(s) Type 1 diabetes; metabolic disease; regenerative medicine Technology or Modality Peptide therapeutics; GLP-1/gastrin dual agonism Development Stage Preclinical Deal Value Financial terms were not disclosed Geography Global What Happened Zealand Pharma licensed its GLP-1/gastrin dual-agonist peptide platform and associated preclinical package to Elvinix for development in type 1 diabetes. Why It Matters The programme is intended to support pancreatic beta-cell regeneration, offering a potentially disease-modifying approach rather than solely replacing insulin or managing glucose. Supporting Context Combining GLP-1 and gastrin activity has been investigated as a strategy for promoting beta-cell growth and improving pancreatic function. Strategic Rationale Elvinix gains control of an early regenerative diabetes platform while Zealand can focus resources on its core pipeline and retain potential value from future development. Potential Impact Successful development could introduce a regenerative therapeutic strategy aimed at restoring insulin-producing capacity in type 1 diabetes. Key Takeaway Zealand has out-licensed a regenerative GLP-1/gastrin peptide platform to Elvinix for type 1 diabetes development. What to Watch Preclinical validation, progression toward first-in-human studies and disclosure of development milestones under the licence. Primary Source Zealand Pharma / Elvinix Relevant Date 15 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Flow Neuroscience has launched FL-100 in the United States, bringing an FDA-approved at-home transcranial direct-current stimulation treatment to adults with moderate-to-severe major depressive disorder. The prescription device delivers non-invasive electrical stimulation at home and is intended to provide a drug-free treatment option for eligible adults with depression. The US launch expands access to neuromodulation outside clinic-based settings and represents a significant commercial milestone for home-based digital and device-enabled mental healthcare. Field Content Alert Type Industry Update Product Name FL-100 Company Flow Neuroscience Development Type US commercial launch Indication Moderate-to-severe major depressive disorder in adults Therapy Area(s) Psychiatry; mental health; depression Technology or Modality Transcranial direct-current stimulation; neuromodulation Regulatory Status FDA-approved prescription medical device Geography United States What Happened Flow Neuroscience launched its FL-100 at-home tDCS treatment in the United States for adults with moderate-to-severe major depressive disorder. Why It Matters The launch broadens access to a non-pharmacological treatment that can be used at home under prescription rather than requiring repeated clinic-based neuromodulation sessions. Supporting Context Transcranial direct-current stimulation uses low-intensity electrical current applied through scalp electrodes to modulate activity in brain regions associated with depression. Potential Impact At-home treatment could improve convenience and expand the range of options available to patients who cannot tolerate, do not respond to or prefer alternatives to medication. Key Takeaway Flow Neuroscience has begun US commercialisation of an FDA-approved at-home tDCS treatment for depression. What to Watch Prescription uptake, payer coverage, patient adherence and real-world evidence on effectiveness outside controlled clinical settings. Primary Source Flow Neuroscience Relevant Date 16 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

UpFront Diagnostics has secured CE mark approval for LVOne, a rapid blood test designed to identify large-vessel-occlusion stroke in pre-hospital settings. LVOne is intended to support faster triage of suspected stroke patients by identifying biomarkers associated with large-vessel occlusion from a blood sample before hospital arrival. The CE mark enables European commercialisation and could support more rapid routing of eligible patients to specialist stroke centres for thrombectomy assessment. Field Content Alert Type Approval Product Name LVOne Company UpFront Diagnostics Regulatory Authority European CE marking framework Approval Type CE mark approval Intended Use Rapid blood-based identification of large-vessel-occlusion stroke in suspected stroke patients Therapy Area(s) Neurology; stroke; diagnostics Technology or Modality In-vitro diagnostic blood test Geography Europe What Happened UpFront Diagnostics secured CE mark approval for LVOne, enabling commercialisation of the rapid blood test in Europe. Why It Matters Large-vessel-occlusion stroke requires rapid specialist intervention, and an earlier blood-based indication could support faster patient triage and transfer decisions. Supporting Context LVOne is designed for use close to the patient, including pre-hospital settings, to help identify patients who may need assessment for mechanical thrombectomy. Key Takeaway LVOne has received CE mark approval, opening a European commercial pathway for rapid blood-based stroke triage. What to Watch Commercial rollout, adoption by emergency medical services and real-world evidence showing whether LVOne shortens time to specialist stroke treatment. Primary Source UpFront Diagnostics Relevant Date 16 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Escugen Biotechnology and Sovran Biosciences have expanded their oncology collaboration with a co-development agreement for a pan-tumour bispecific antibody-drug conjugate. The programme will combine MICA/B targeting with a second tumour-associated target using an AND-gated design intended to improve tumour selectivity across multiple cancer types. The agreement advances the companies' relationship from research collaboration into joint development of a potentially first-in-class ADC programme, with financial terms undisclosed. Field Content Alert Type Deal Companies Escugen Biotechnology; Sovran Biosciences Deal Type Co-development agreement Asset or Company Pan-tumour bispecific antibody-drug conjugate programme Therapy Area(s) Oncology; solid tumours Technology or Modality Bispecific antibody-drug conjugate; AND-gated targeting Targets MICA/B plus a second tumour-associated target Deal Value Financial terms were not disclosed Geography Global What Happened Escugen and Sovran expanded their existing collaboration into a co-development agreement for a bispecific ADC intended to target multiple tumour types. Why It Matters The programme uses dual-target recognition designed to increase tumour selectivity, potentially improving therapeutic index compared with conventional single-target ADCs. Supporting Context The AND-gated strategy requires recognition of MICA/B and a second tumour-associated target to enhance preferential activity against cancer cells. Strategic Rationale Escugen and Sovran are combining complementary antibody-engineering and oncology-development capabilities to advance a differentiated ADC platform. Potential Impact If successful, the approach could support development of a broadly applicable ADC with improved specificity across multiple solid tumours. Key Takeaway Escugen and Sovran have moved into joint development of a pan-tumour bispecific ADC based on dual-target recognition. What to Watch Selection of the second tumour target, candidate nomination and progression into preclinical and clinical development. Primary Source Escugen Biotechnology / Sovran Biosciences Relevant Date 16 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

GSK has acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma in a transaction worth up to $750 million. The programme is designed to engage T cells against multiple myeloma through a trispecific antibody approach, adding another differentiated immuno-oncology asset to GSK's haematology pipeline. Chimagen is eligible for upfront and milestone payments worth up to $750 million, while GSK will assume responsibility for further global development and commercialisation of the programme. Field Content Alert Type Deal Companies GSK; Chimagen Biosciences Deal Type Global rights acquisition / licensing agreement Asset or Company Trispecific T-cell engager programme Therapy Area(s) Oncology; haematology; multiple myeloma Technology or Modality Trispecific T-cell engager Deal Value Up to US$750 million in upfront and milestone payments Geography Global What Happened GSK acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma. Why It Matters The deal adds a potentially differentiated next-generation immunotherapy to GSK's multiple myeloma pipeline and strengthens its position in haematologic oncology. Supporting Context The programme uses a trispecific antibody design intended to direct T cells against tumour targets associated with multiple myeloma. Strategic Rationale GSK gains control of an innovative early-stage oncology programme while Chimagen receives near- and long-term economics tied to development and commercial success. Potential Impact Successful development could provide a new treatment approach for patients with multiple myeloma and strengthen competition in the T-cell engager field. Key Takeaway GSK is committing up to US$750 million for global rights to Chimagen's trispecific T-cell engager programme in multiple myeloma. What to Watch Entry into clinical development, early safety and efficacy data and positioning against other T-cell engager and cell-therapy approaches in multiple myeloma. Primary Source GSK Relevant Date 15 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Sanofi and Cheplapharm have agreed a major mature-medicines transaction covering 20 products and three manufacturing sites in France, Hungary and Singapore. Cheplapharm will take responsibility for the portfolio and manufacturing facilities, while Sanofi will receive a 26.4% equity stake in Cheplapharm as part of the strategic partnership. The transaction allows Sanofi to further concentrate resources on innovative medicines while transferring established products and manufacturing infrastructure to a company specialised in mature pharmaceutical brands. Field Content Alert Type Deal Companies Sanofi; Cheplapharm Deal Type Portfolio and manufacturing asset transfer; strategic partnership Asset or Company 20 mature medicines and three manufacturing sites Manufacturing Sites France; Hungary; Singapore Therapy Area(s) Multiple therapeutic areas Technology or Modality Mature pharmaceutical products and manufacturing operations Deal Value Sanofi to receive a 26.4% equity stake in Cheplapharm; additional financial terms not disclosed Geography Global What Happened Sanofi and Cheplapharm agreed to transfer 20 mature medicines and three manufacturing sites to Cheplapharm, with Sanofi receiving a 26.4% equity stake in the company. Why It Matters The transaction represents a substantial portfolio and manufacturing realignment and allows Sanofi to focus more resources on innovative medicines while maintaining economic participation through its Cheplapharm stake. Supporting Context Cheplapharm specialises in acquiring and managing established pharmaceutical brands and mature medicines. Strategic Rationale Sanofi is simplifying its portfolio and manufacturing footprint, while Cheplapharm gains a significant group of established products and production assets. Potential Impact The transaction could reshape supply and commercial management of the transferred medicines while strengthening Cheplapharm's manufacturing and product portfolio. Key Takeaway Sanofi is transferring 20 mature medicines and three manufacturing sites to Cheplapharm in exchange for a significant equity stake. What to Watch Regulatory approvals, completion of the transaction and integration of the medicines and manufacturing sites into Cheplapharm. Primary Source Sanofi Relevant Date 14 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com